Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.44 |
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31128553 | 1.00 | AR (0.51) | ARLMNAMAPK1HTTRAB9A | |
| SCHEMBL7285654 | 0.85 | KIF11 (0.54) | ARRAB9AKDM1AALDH1A1 | |
| SCHEMBL9061902 | 0.85 | KIF11 (0.54) | ARRAB9AKDM1AALDH1A1 | |
| SCHEMBL350999 | 0.84 | AR (0.51) | ARNR3C1PGRNR3C2KDM1A | |
| SCHEMBL9644087 | 0.83 | AR (0.59) | ARRAB9ASLC6A4 | |
| SCHEMBL509522 | 0.81 | AR (0.66) | ARKDM1AKDM4EUSP2ALDH1A1 | |
| SCHEMBL29490258 | 0.81 | AR (0.66) | ARKDM1AKDM4EUSP2ALDH1A1 | |
| SCHEMBL12230360 | 0.80 | AR (0.39) | ARLMNAMAPK1HTTRAB9A | |
| SCHEMBL2437123 | 0.80 | RAB9A (0.46) | LMNAMAPK1HTTRAB9ATUBB1 | |
| SCHEMBL16987880 | 0.80 | USP30 (0.49) | ARNR3C1PGRNR3C2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118054087-B | Electrolyte, electrolyte injection method and lithium metal battery | 蜂巢能源科技股份有限公司 | 2024-07-19 | — | — | CN | claimed |
| CN-118054087-A | Electrolyte, electrolyte injection method and lithium metal battery | 蜂巢能源科技股份有限公司 | 2024-05-17 | — | — | CN | claimed |
| US-20170342070-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | claimed |
| EP-3105218-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Incyte Corporation (US) | 2016-12-21 | — | — | EP | claimed |
| WO-2015123465-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-20 | — | — | WO | claimed |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | claimed |
| US-20250129016-A1 | PHOTOREDOX METHODS FOR RADIOCYANATION OF ARENES AND USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-04-24 | — | — | US | disclosed |
| CN-118054087-B | Electrolyte, electrolyte injection method and lithium metal battery | 蜂巢能源科技股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-4395828-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| CN-115677723-B | 5-HT2A receptor antagonists and their use for treating central nervous system disorders | 瀚远医药有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118054087-A | Electrolyte, electrolyte injection method and lithium metal battery | 蜂巢能源科技股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-4997942-A | 2,4-disubstituted pyrazine derivatives, pyrimidine derivatives, and liquid crystal containing the same | DAINIPPON INK AND CHEMICAL, INC. (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0339252-A2 | 2,5-disubstituted pyrazine derivatives, pyrimidine derivatives, and liquid crystal containing the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1989-11-02 | — | — | EP | disclosed |
| US-4865763-A | LOW TEMPERATURE STABILITY | CHISSO CORPORATION (JP) | 1989-09-12 | — | — | US | disclosed |
| US-4765924-A | SMECTIC PHASE FORMING INHIBITION | CHISSO CORPORATION (JP) | 1988-08-23 | — | — | US | disclosed |
| US-4710315-A | USE WITH MULTIPLEXIBLE DISPLAYS HAVING HIGH DENSITY IMAGES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1987-12-01 | — | — | US | disclosed |
| EP-0233706-A2 | Halogen-containing heterocyclic compounds and liquid crystal compositions containing them | Chisso Corporation (JP) | 1987-08-26 | — | — | EP | disclosed |
| WO-1985004874-A1 | ANISOTROPIC COMPOUNDS AND LIQUID CRYSTAL MIXTURES THEREWITH | MERCK PATENT GMBH (DE) | 1985-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | AR 937/4885LMNA 2442/4885MAPK1 3969/4885 |
| US-20170342070-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | AR 937/4885LMNA 2442/4885MAPK1 3969/4885 |
| US-20250129016-A1 | PHOTOREDOX METHODS FOR RADIOCYANATION OF ARENES AND USE THEREOF | RCC2, PPOX, FTO | AR 53/4885LMNA 2919/4885MAPK1 2762/4885 |
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | AR 853/4885LMNA 2472/4885MAPK1 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.